Research Article Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions S. D. Dowall,1 V. A. Graham,1 K. Corbin-Lickfett,2 C. Empig,2 K. Schlunegger,2 C. B. Bruce,1 L. Easterbrook,1 and R. Hewson1
1Public Health England, Porton Down, Wiltshire, Salisbury SP4 0JG, UK 2Peregrine Pharmaceuticals, Inc., Tustin, CA 92780, USA
Received 25 February 2014; Revised 20 June 2014; Accepted 3 September 2014
Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.[more]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.